🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07803133
Starting soon Not applicable

PENG Block Versus Intrathecal Morphine for Early Postoperative Recovery After Total Hip Arthroplasty

NCT07803133 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-09-09

Condition(s) studied

Postoperative Pain

Investigational drug(s) / intervention(s)

Pericapsular nerve group (PENG) blockIntrathecal Morphine →

Pericapsular nerve group (PENG) block: Participants will receive an ultrasound-guided pericapsular nerve group (PENG) block after spinal anesthesia. The total injectate volume will be 20 mL, with an intended dose of 100 mg bupivacaine (20 mL of 0.5% bupivacaine). The bupivacaine dose will be reduced when necessary to ensure that the total bupivacaine dose, including the dose administered for spinal anesthesia, does not exceed 2 mg/kg. When dose reduction is required, 0.9% saline will be added to maintain a total injectate volume of 20 mL.

Intrathecal Morphine: 100 micrograms of preservative-free morphine administered intrathecally during spinal anesthesia

Study summary

The goal of this clinical trial is to compare the PENG block with intrathecal morphine for early postoperative recovery and pain control in adults undergoing elective total hip arthroplasty. The main question it aims to answer is:

Is there a difference between PENG block and intrathecal morphine in quality of recovery 24 hours after surgery, as measured by the Quality of Recovery-15 (QoR-15) questionnaire?

Researchers will also compare postoperative pain, opioid use, mobilization, motor function, and treatment-related side effects between the two groups.

Participants will be randomly assigned to receive either a PENG block or intrathecal morphine in addition to spinal anesthesia and standard multimodal pain treatment. Participants will complete the QoR-15 questionnaire before surgery and 24 hours after surgery. Pain scores, opioid use, mobilization, motor function, and side effects will be assessed during the first 24 hours after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-85 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective primary unilateral total hip arthroplasty * Planned spinal anesthesia * Ability to understand and complete the Quality of Recovery-15 (QoR-15) questionnaire and Numeric Rating Scale (NRS) pain assessments * Provision of written informed consent Exclusion Criteria: * Contraindication to spinal anesthesia or PENG block * Known allergy or hypersensitivity to local anesthetics or morphine * Coagulation disorder * Therapeutic anticoagulant use * Infection at the planned injection site * Chronic opioid use * History of substance abuse * Severe cognitive impairment that prevents reliable completion of study assessments * Advanced hepatic or renal failure * ASA physical status IV or higher * Revision total hip arthroplasty * Surgery for pathological fracture or tumor * Pregnancy * Requirement for general anesthesia * Refusal to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital Erzincan Erzincan

More Erzincan Binali Yildirim Universitesi trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07803133 on ClinicalTrials.gov ↗ ← All trials in Turkey